Nykredit A S Acquires Shares of 93,139 Becton, Dickinson and Company $BDX

Key Points

• Nykredit A/S acquired 93,139 shares of Becton, Dickinson and Company in the second quarter, valued at approximately $14.1 million. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly EPS of $3.23, beating estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• BD declared a quarterly dividend of $1.05 per share, representing an annualized payout of $4.20 and a 2.3% yield. Analysts have a consensus “Hold” rating and an average price target of $187.67.

Nykredit A S acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 93,139 shares of the medical instruments supplier's stock, valued at approximately $14,095,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brown Lisle Cummings Inc. lifted its holdings in Becton, Dickinson and Company by 9.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock valued at $97,000 after purchasing an additional 54 shares during the last quarter. Elevation Point Wealth Partners LLC raised its position in shares of Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC lifted its stake in shares of Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock worth $834,000 after buying an additional 62 shares during the last quarter. BOK Financial Private Wealth Inc. boosted its holdings in shares of Becton, Dickinson and Company by 7.3% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier's stock worth $162,000 after buying an additional 73 shares during the period. Finally, Keating Financial Advisory Services Inc. grew its stake in Becton, Dickinson and Company by 41.6% in the 2nd quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 74 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $180.62 on Friday. The company has a market cap of $49.77 billion, a price-to-earnings ratio of 54.40, a PEG ratio of 12.75 and a beta of 0.21. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a fifty day moving average price of $175.47 and a 200-day moving average price of $160.74.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 126.51%.

Analyst Ratings Changes

BDX has been the subject of a number of research analyst reports. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Weiss Ratings restated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. The Goldman Sachs Group lowered their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 27th. Finally, Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $187.67.

Insider Activity

In other news, EVP Michael Garrison sold 1,100 shares of the business's stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares of the company's stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,005 shares of company stock valued at $1,423,580. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.